Combating resistance while maintaining innovation: The future of antimicrobial stewardship

Future Microbiology

Volumn 14, Issue 15, 2019, Pages 1331-1341

  Vickers, Richard J ^a   Bassetti, Matteo ^b   Clancy, Cornelius J ^c   Garey, Kevin W ^d   Greenberg, David E ^e   Nguyen, Minh Hong ^c   Roblin, David ^a   Tillotson, Glenn S ^f   Wilcox, Mark H ^g  

^a SUMMIT PLC   (United Kingdom)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f GST Micro LLC   (United States)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

antibiotic cost; antimicrobial stewardship; novel mechanism antibiotics

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP; CLINICAL OUTCOME; DRUG APPROVAL; DRUG USE; HUMAN; PRIORITY JOURNAL; REVIEW; DRUG DEVELOPMENT; DRUG RESISTANCE; ECONOMICS; GLOBAL HEALTH; HOSPITAL; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL STEWARDSHIP; DRUG DISCOVERY; DRUG RESISTANCE; GLOBAL HEALTH; HOSPITALS; HUMANS;

EID: 85077108569     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2019-0227     Document Type: Review

References (85)

1. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 163(1), 184-194 (2011).
2. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae Carbapenemase-producing K pneumoniae: A case report and review of literature. Open Forum Infect. Dis. (2017). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493938/
3. MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation. Antimicrob. Agents Chemother. 61(12), e01183-01117 (2017).
4. Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: Progress, challenges and next steps. J. Antibiot. 70(12), 1087-1096 (2017).
5. Ardal C, Rottingen JA, Opalska A, Van Hengel AJ, Larsen J. Pull incentives for antibacterial drug development: An analysis by the transatlantic task force on antimicrobial resistance. Clin. Infect. Dis. 65(8), 1378-1382 (2017).
6. Nielsen TB, Brass EP, Gilbert DN, Bartlett JG, Spellberg B. sustainable discovery and development of antibiotics - is a nonprofit approach the future? N. Engl. J. Med. 381(6), 503-505 (2019).
7. McGowan J, Gerding D. Does antibiotic restriction prevent resistance. New Horizons 4(3), 370-376 (1996).
8. CDC. White House National action plan for combating antibotic resistant bacteria. (2015) https://www.cdc.gov/drugresistance/pdf /national action plan for combating antibotic-resistant bacteria.pdf
9. CDC. Core elements of hospital antibiotic stewardship programs. (2014) http://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html
10. Pulcini C. Antibiotic stewardship: A European perspective. FEMS Microbiol. Lett. 364(23), 1-4 (2017).
11. Dyar OJ, Huttner B, Schouten J, Pulcini C. Esgap. What is antimicrobial stewardship? Clin. Microbiol. Infect. 23(11), 793-798 (2017).
12. Barlam TF, Cosgrove SE, Abbo LM et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin. Infect. Dis. 62(10), e51-77 (2016).
13. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin. Infect. Dis. 25(2), 230-239 (1997).
14. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(5), 1983-1986 (2009).
15. Garau J. Impact of antibiotic restrictions: The ethical perspective. Clin. Microbiol. Infect. 12(Suppl. 5), 16-24 (2006).
16. Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: Systematic review and meta-analysis. BMC Infect. Dis. 15, 395-406 (2015).
17. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect. Dis. 17(1), 279-292 (2017).
18. Burke JP. Antibiotic resistance-squeezing the balloon? JAMA 280(14), 1270-1271 (1998).
19. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280(14), 1233-1237 (1998).
20. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: Experience at one hospital with squeezing the resistance balloon at multiple sites. Clin. Infect. Dis. 34(4), 499-503 (2002).
21. Davey P, Marwick CA, Scott CL et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev. 2, CD003543 (2017).
22. Reed EE, Stevenson KB, West JE, Bauer KA, Goff DA. Impact of formulary restriction with prior authorization by an antimicrobial stewardship program. Virulence 4(2), 158-162 (2013).
23. Davey P, Brown E, Charani E et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev. (4), CD003543 (2013).
24. Tamma PD, Avdic E, Keenan JF et al. What is the more effective antibiotic stewardship intervention: Preprescription authorization or postprescription review with feedback? Clin. Infect. Dis. 64(5), 537-543 (2017).
25. Dik JW, Hendrix R, Poelman R et al. Measuring the impact of antimicrobial stewardship programs. Ex. Rev. Anti-infect. Ther. 14(6), 569-575 (2016).
26. Brotherton AL. Metrics of antimicrobial stewardship programs. Med. Clin. North Am. 102(5), 965-976 (2018).
27. Dodds Ashley ES, Kaye KS, DePestel DD, Hermsen ED. Antimicrobial stewardship: Philosophy versus practice. Clin. Infect. Dis. 59(Suppl. 3), S112-S121 (2014).
28. Emberger J, Tassone D, Stevens MP, Markley JD. The current state of antimicrobial stewardship: Challenges, successes, and future directions. Curr. Infect. Dis. Rep. 20(9), 31 (2018).
29. Spellberg B, Bartlett JG, Gilbert DN. How to pitch an antibiotic stewardship program to the hospital C-suite. Open Forum Infect. Dis. 3(4), (2016).ofw210
30. Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: The evolution of programmatic strategies and barriers. Infect. Control Hosp. Epidemiol. 32(4), 367-374 (2011).
31. Abbo L, Lo K, Sinkowitz-Cochran R et al. Antimicrobial stewardship programs in Florida's acute care facilities. Infect. Control Hosp. Epidemiol. 34(6), 634-637 (2013).
32. Akpan MR, Ahmad R, Shebl NA, Ashiru-Oredope D. A review of quality measures for assessing the impact of antimicrobial stewardship programs in hospitals. Antibiotics 5(1), 5-21 (2016).
33. Schweitzer VA, van Heijl I, van Werkhoven CH et al. The quality of studies evaluating antimicrobial stewardship interventions: A systematic review. Clin Microbiol Infect 25(5), 555-561 (2018).
34. Baur D, Gladstone BP, Burkert F et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: A systematic review and meta-analysis. Lancet Infect. Dis. 17(9), 990-1001 (2017).
35. McKellar MR, Fendrick AM. Innovation of novel antibiotics: An economic perspective. Clin. Infect. Dis. 59(Suppl. 3), S104-S107 (2014).
36. Parente DM, Morton J. Role of the pharmacist in antimicrobial stewardship. Med. Clin. North Am. 102(5), 929-936 (2018).
37. Cunha CB, Varughese CA, Mylonakis E. Antimicrobial stewardship programs (ASPs): The devil is in the details. Virulence 4(2), 147-149 (2013).
38. Nagel JL, Stevenson JG, Eiland EH 3rd, Kaye KS. Demonstrating the value of antimicrobial stewardship programs to hospital administrators. Clin. Infect. Dis. 59(Suppl. 3), S146-S153 (2014).
39. US Department of Health and Human Services C. Antibiotic use in the united states, 2018 update: Progress and opportunities. Atlanta, GA (2019).
40. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: A visionary approach. Intensive Care Med. 43(10), 1464-1475 (2017).
41. Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect. drug Dis. 11, 1461-1472 (2018).
42. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: The TANGO II randomized clinical trial. Infect. Dis. Ther. (2018).
43. Shields R. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob. Agents Chemother. 61(8), e00883-00817 (2017).
44. van Duin D, Lok JJ, Earley M et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin. Infect. Dis. 66(2), 163-171 (2018).
45. Kadri SS, Adjemian J, Lai YL et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin. Infect. Dis. 67(12), 1803-1814 (2018).
46. Schulz LT, Kim SY, Hartsell A, Rose WE. Antimicrobial stewardship during a time of rapid antimicrobial development: Potential impact on industry for future investment. Diagn. Microbiol. Infect. Dis. (2019).
47. Clancy CJ, Potoski BA, Buehrle D, Nguyen MH. Estimating the treatment of carbapenem resistant Enterobacteriaceae infections in the United States using antibiotic prescription data. Open Forum Inf. Dis. (2019).
48. Johnson S, Louie TJ, GerdingDNet al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 59(3), 345-354 (2014).
49. van Schaik W. The human gut resistome. Philos. Trans. R Soc. Lond. B Biol. Sci. 370(1670), 20140087 (2015).
50. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect. 18(Suppl. 6), 21-27 (2012).
51. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12(4), 281-289 (2012).
52. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364(5), 422-431 (2011).
53. Goldenberg SD, Brown S, Edwards L et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: A series of local service evaluations. Eur. J. Clin. Microbiol. Infect. Dis. 35(2), 251-259 (2016).
54. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin. Infect. Dis. 55(Suppl. 2), S121-S126 (2012).
55. Rubio-Terres C, Cobo Reinoso J, Grau Cerrato S et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 34(11), 2213-2223 (2015).
56. Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile Infection. Antimicrob. Agents Chemother. 59(11), 7007-7010 (2015).
57. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J. Antimicrob. Chemother. 69(11), 2901-2912 (2014).
58. Reveles KR, Backo JL, Corvino FA, Zivkovic M, Broderick KC. Fidaxomicin versus vancomycin as a first-line treatment for clostridium difficile-associated diarrhea in specific patient populations: A pharmacoeconomic evaluation. Pharmacotherapy 37(12), 1489-1497 (2017).
59. Miller LG. Another new antibiotic for skin infections and why infectious disease specialists are hypocrites. Clin. Infect. Dis. 68(7), 1223-1224 (2018).
60. Powers JH, Fleming TR. Noninferiority trials: Clinical understandings and misunderstandings. Clin. Investig. (Lond.) 3(3), 215-218 (2013).
61. DiNubile MJ. Noninferior antibiotics: when is "not bad" "good enough"? Open Forum Infect. Dis. 3(3), (2016).ofw110
62. Herath C, Blondeau JM. Do we really understand what we want or need out of antimicrobial stewardship programs. Future Med. Clin. Pract. 10(1), 5-9 (2013).
63. Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015. Ann. Intern. Med. 165(5), 363-372 (2016).
64. Powers JH, Evans SR, Kesselheim AS. Studying new antibiotics for multidrug resistant infections: Are today's patients paying for unproved future benefits? BMJ 360, k587 (2018).
65. WHO. Model list of essential medicines (2017). https://www.who.int/medicines/publications/essentialmedicines/en/
66. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, evolution, and future. Clin. Microbiol. Rev. 27(3), 587-613 (2014).
67. Mullard A. Preclinical antibiotic pipeline gets a pick-me-up. Nat. Rev. Drug Dis. 16(11), 741-742 (2017).
68. Pew Trust. Antibiotics currently in global clinical development (2018). https: //www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-development
69. Martin-Loeches I, Dale GE, Torres A. Murepavadin: A new antibiotic class in the pipeline. Exp. Rev. Anti-infect. Ther. 16(4), 259-268 (2018).
70. Tse BN, Adalja AA, Houchens C, Larsen J, Inglesby TV, Hatchett R. Challenges and opportunities of nontraditional approaches to treating bacterial infections. Clin. Infect. Dis. 65(3), 495-500 (2017).
71. Boucher HW, Ambrose PG, Chambers HF et al. White paper: Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. J. Infect. Dis. 216(2), 228-236 (2017).
72. Kaye KS, Bhowmick T, Metallidis S et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I randomized clinical trial. JAMA 319(8), 788-799 (2018).
73. de Kraker MEA, Sommer H, de Velde F et al. Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms: A white paper from COMBACTE's STAT-Net. Clin. Infect. Dis. 67(12), 1922-1931 (2018).
74. McDonnell A, Rex JH, Goossens H, Bonten M, Fowler VG Jr, Dane A. Efficient delivery of investigational antibacterial agents via sustainable clinical trial networks. Clin. Infect. Dis. 63(Suppl. 2), S57-S59 (2016).
75. Dik JH, Poelman R, Friedrich AW, Niesters HGM, Rossen JWA, Sinha B. Integrated stewardship model comprising antimicrobial, infection prevention, and diagnostic stewardship (AID stewardship). J. Clin. Microbiol. 55(11), 3306-3307 (2017).
76. Garau J, Bassetti M. Role of pharmacists in antimicrobial stewardship programmes. Int. J. Clin. Pharm. 40(5), 948-952 (2018).
77. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. Lancet Infect. Dis. 14(6), 498-509 (2014).
78. Vincent JL, Bassetti M, Francois B et al. Advances in antibiotic therapy in the critically ill. Critical Care 20(1), 133-146 (2016).
79. Luyt CE, Brechot N, Trouillet JL, Chastre J. Antibiotic stewardship in the intensive care unit. Critical Care 18(5), 480-492 (2014).
80. Rawson TM, O'Hare D, Herrero P et al. Delivering precision antimicrobial therapy through closed-loop control systems. J. Antimicrob. Chemother. 73(4), 835-843 (2018).
81. Tsalik EL, Bonomo RA, Fowler VG Jr. New molecular diagnostic approaches to bacterial infections and antibacterial resistance. Annu. Rev. Med. 69, 379-394 (2018).
82. Timbrook TT, Spivak ES, Hanson KE. Current and future opportunities for rapid diagnostics in antimicrobial stewardship. Med. Clin. North Am. 102(5), 899-911 (2018).
83. Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin. Infect. Dis. 59(Suppl. 3), S134-S145 (2014).
84. Edmiston CE, Garcia R, Barnden M, DeBaun B, Johnson HB. Rapid diagnostics for bloodstream infections: A primer for infection preventionists. Am. J. Infect. Control 46(9), 1060-1068 (2018).
85. Kmietowicz Z. New antibiotics: NHS will test "pay for usefulness" model to stimulate research. BMJ 366, l4610 (2019).